{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:51:17Z","timestamp":1768344677342,"version":"3.49.0"},"reference-count":284,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.autrev.2014.01.052","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T23:16:06Z","timestamp":1390346166000},"page":"331-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Unmet needs in the treatment of autoimmunity: From aspirin to stem cells"],"prefix":"10.1016","volume":"13","author":[{"given":"Christopher","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2014.01.052_bb0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaut.2012.10.004","article-title":"Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis","volume":"41","author":"Wang","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jaut.2012.09.002","article-title":"Epigenetics, autoimmunity and hematologic malignancies: a comprehensive review","volume":"39","author":"Ngalamika","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0015","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.autrev.2012.09.003","article-title":"Emerging and critical issues in the pathogenesis of lupus","volume":"12","author":"Gatto","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.autrev.2012.07.014","article-title":"New genetic interpretation of old diseases","volume":"12","author":"Touitou","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaut.2012.05.001","article-title":"Criteria for environmentally associated autoimmune diseases","volume":"39","author":"Miller","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jaut.2012.05.002","article-title":"Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop","volume":"39","author":"Miller","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0035","doi-asserted-by":"crossref","first-page":"J71","DOI":"10.1016\/j.jaut.2011.12.007","article-title":"Sex gender and autoimmunity","volume":"38","author":"Shoenfeld","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0040","doi-asserted-by":"crossref","first-page":"J254","DOI":"10.1016\/j.jaut.2011.12.001","article-title":"Sex differences and genomics in autoimmune diseases","volume":"38","author":"Amur","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0045","doi-asserted-by":"crossref","first-page":"J187","DOI":"10.1016\/j.jaut.2011.11.012","article-title":"The X chromosome and immune associated genes","volume":"38","author":"Bianchi","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0050","doi-asserted-by":"crossref","first-page":"J156","DOI":"10.1016\/j.jaut.2011.11.003","article-title":"Twin studies in autoimmune disease: genetics, gender and environment","volume":"38","author":"Bogdanos","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0055","doi-asserted-by":"crossref","first-page":"A493","DOI":"10.1016\/j.autrev.2011.11.027","article-title":"The role of environmental estrogens and autoimmunity","volume":"11","author":"Chighizola","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0060","doi-asserted-by":"crossref","first-page":"A531","DOI":"10.1016\/j.autrev.2011.11.024","article-title":"The X chromosome and the sex ratio of autoimmunity","volume":"11","author":"Selmi","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0065","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.autrev.2011.11.017","article-title":"Genes, tolerance and systemic autoimmunity","volume":"11","author":"Singh","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0070","doi-asserted-by":"crossref","first-page":"J135","DOI":"10.1016\/j.jaut.2011.11.001","article-title":"Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus","volume":"38","author":"Strickland","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0075","doi-asserted-by":"crossref","first-page":"A386","DOI":"10.1016\/j.autrev.2011.11.012","article-title":"Geoepidemiology, gender and autoimmune disease","volume":"11","author":"Moroni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.autrev.2011.11.008","article-title":"The viral enterprises in autoimmunity: conversion of target cells into de novo APCs is the presage to autoimmunity","volume":"11","author":"Temajo","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0085","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2011.10.022","article-title":"Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?","volume":"11","author":"Costenbader","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.autrev.2011.10.003","article-title":"The genomics of autoimmune disease in the era of genome-wide association studies and beyond","volume":"11","author":"Lessard","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0095","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.autrev.2011.05.007","article-title":"Genetic background of multiple sclerosis","volume":"11","author":"Sadovnick","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0100","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.autrev.2010.03.001","article-title":"X chromosome monosomy in primary and overlapping autoimmune diseases","volume":"11","author":"Svyryd","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0105","first-page":"230","article-title":"Increased nitric oxide levels in patients with rheumatoid arthritis","volume":"23","author":"Ueki","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0110","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000139248","article-title":"Suppressive effects of eugenol and ginger oil on arthritic rats","volume":"49","author":"Sharma","year":"1994","journal-title":"Pharmacology"},{"key":"10.1016\/j.autrev.2014.01.052_bb0115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11926-012-0295-x","article-title":"Acupuncture in the treatment of rheumatic diseases","volume":"14","author":"Amezaga Urruela","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2014.01.052_bb0120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jep.2008.11.018","article-title":"Extract of the Chinese herbal formula Huo Luo Xiao Ling Dan inhibited adjuvant arthritis in rats","volume":"121","author":"Zhang","year":"2009","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10787-011-0080-x","article-title":"Modulation of lipopolysaccharide-induced pro-inflammatory mediators by an extract of Glycyrrhiza glabra and its phytoconstituents","volume":"19","author":"Thiyagarajan","year":"2011","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.autrev.2014.01.052_bb0130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.phymed.2010.08.001","article-title":"Dual inhibitory effect of Glycyrrhiza glabra (GutGard) on COX and LOX products","volume":"18","author":"Chandrasekaran","year":"2011","journal-title":"Phytomedicine"},{"key":"10.1016\/j.autrev.2014.01.052_bb0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jep.2006.10.012","article-title":"Glabrol, an acyl-coenzyme A: cholesterol acyltransferase inhibitor from licorice roots","volume":"110","author":"Choi","year":"2007","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0140","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1745-7254.2006.00346.x","article-title":"Neuroprotective effects of roasted licorice, not raw form, on neuronal injury in gerbil hippocampus after transient forebrain ischemia","volume":"27","author":"Hwang","year":"2006","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.autrev.2014.01.052_bb0145","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bbrc.2006.05.035","article-title":"Anti-inflammatory effect of roasted licorice extracts on lipopolysaccharide-induced inflammatory responses in murine macrophages","volume":"345","author":"Kim","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0150","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1124\/mol.59.5.1196","article-title":"Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor-kappa B activities","volume":"59","author":"Sylvester","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0155","first-page":"327","article-title":"A prospective, controlled, double-blind, cross-over study of Tripterygium wilfordii hook F in treatment of rheumatoid arthritis","volume":"102","author":"Tao","year":"1989","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.autrev.2014.01.052_bb0160","first-page":"36","article-title":"Mechanism of treating rheumatoid arthritis with Tripterygium wilfordii hook. II. Effect on PGE2 secretion","volume":"11","author":"Tao","year":"1989","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"10.1016\/j.autrev.2014.01.052_bb0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0049-0172(97)80040-6","article-title":"A potential new treatment for rheumatoid arthritis: thunder god vine","volume":"26","author":"Lipsky","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0170","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1211\/jpp\/61.08.0013","article-title":"Inhibition of inducible nitric oxide synthesis by Cimicifuga racemosa (Actaea racemosa, black cohosh) extracts in LPS-stimulated RAW 264.7 macrophages","volume":"61","author":"Schmid","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0175","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1139\/Y09-091","article-title":"Aqueous extracts of Cimicifuga racemosa and phenolcarboxylic constituents inhibit production of proinflammatory cytokines in LPS-stimulated human whole blood","volume":"87","author":"Schmid","year":"2009","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0180","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1021\/jm9006164","article-title":"Identification of the bioactive constituent and its mechanisms of action in mediating the anti-inflammatory effects of black cohosh and related Cimicifuga species on human primary blood macrophages","volume":"52","author":"Yang","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.autrev.2014.01.052_bb0185","first-page":"632","article-title":"Preliminary study on antirheumatic activity of curcumin (diferuloyl methane)","volume":"71","author":"Deodhar","year":"1980","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.autrev.2014.01.052_bb0190","first-page":"27","article-title":"Bromelains therapy in rheumatoid arthritis","volume":"67","author":"Cohen","year":"1964","journal-title":"Pa Med J"},{"key":"10.1016\/j.autrev.2014.01.052_bb0195","first-page":"125","article-title":"Asiaticoside extracted from Centella asiatica and its therapeutic uses in cicatrization of experimental and refractory wounds (leprosy, cutaneous tuberculosis and lupus)","volume":"11","author":"Boiteau","year":"1956","journal-title":"Therapie"},{"key":"10.1016\/j.autrev.2014.01.052_bb0200","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0378-8741(97)01525-0","article-title":"Depletion of tumor necrosis factor-alpha in mice by Nyctanthes arbor-tristis","volume":"56","author":"Paul","year":"1997","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1081\/IPH-120026442","article-title":"Swertia chirayita mediated modulation of interleukin-1beta, interleukin-6, interleukin-10, interferon-gamma, and tumor necrosis factor-alpha in arthritic mice","volume":"25","author":"Kumar","year":"2003","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0210","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2210-2-7","article-title":"Antinociceptive and anti-inflammatory effects of Crocus sativus L. stigma and petal extracts in mice","volume":"2","author":"Hosseinzadeh","year":"2002","journal-title":"BMC Pharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0215","first-page":"890","article-title":"Phytochemical investigation and evaluation of anti-inflammatory and anti-arthritic activities of essential oil of Strobilanthus ixiocephala Benth","volume":"41","author":"Agarwal","year":"2003","journal-title":"Indian J Exp Biol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0378-8741(03)00143-0","article-title":"Free radical scavenging activity of the alcoholic extract of Trewia polycarpa roots in arthritic rats","volume":"88","author":"Chamundeeswari","year":"2003","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0225","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cyto.2003.11.016","article-title":"Madimadi, Korean folk medicine, blocks TNF-alpha, IL-1beta, and IL-8 production by activated human immune cells","volume":"25","author":"Kim","year":"2004","journal-title":"Cytokine"},{"key":"10.1016\/j.autrev.2014.01.052_bb0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jep.2004.06.025","article-title":"Inhibitory effects of the Gentiana macrophylla (Gentianaceae) extract on rheumatoid arthritis of rats","volume":"95","author":"Yu","year":"2004","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0235","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1055\/s-2001-16496","article-title":"Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms","volume":"67","author":"Koch","year":"2001","journal-title":"Planta Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0240","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2004.04.053","article-title":"Anti-angiogenic effects of Shiraiachrome A, a compound isolated from a Chinese folk medicine used to treat rheumatoid arthritis","volume":"494","author":"Tong","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0245","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/ard.13.3.190","article-title":"History of the use of colchicum and related medicaments in gout; with suggestions for further research","volume":"13","author":"Hartung","year":"1954","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0250","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1113\/jphysiol.1908.sp001257","article-title":"Colchicine with special reference to its mode of action and effect on bone-marrow","volume":"37","author":"Dixon","year":"1908","journal-title":"J Physiol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/jez.1401030103","article-title":"A cytological study of mitosis in the cornea of Triturus viridescens during recovery after colchicine treatment","volume":"103","author":"Peters","year":"1946","journal-title":"J Exp Zool"},{"key":"10.1016\/j.autrev.2014.01.052_bb0260","first-page":"207","article-title":"Antidotal efficacy of glutamate and aspartate for colchicine toxicity","volume":"39","author":"Wang","year":"1997","journal-title":"Vet Hum Toxicol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0265","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: the dark side of an ancient drug","volume":"48","author":"Finkelstein","year":"2010","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.autrev.2014.01.052_bb0270","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0049-0172(85)90037-X","article-title":"The history of gold therapy in rheumatoid disease","volume":"14","author":"Kean","year":"1985","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0275","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/ard.8.2.132","article-title":"Copper and gold salts in rheumatoid arthritis","volume":"8","author":"Forestier","year":"1949","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0280","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio773","article-title":"Noble metals strip peptides from class II MHC proteins","volume":"2","author":"De Wall","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0285","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0006-2952(95)02030-6","article-title":"Auranofin inhibits the induction of interleukin 1 beta and tumor necrosis factor alpha mRNA in macrophages","volume":"50","author":"Bondeson","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0290","first-page":"CD000520","article-title":"Injectable gold for rheumatoid arthritis","author":"Clark","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0295","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/112067211002000421","article-title":"Corneal chrysiasis: in vivo confocal microscopy analysis","volume":"20","author":"Paladini","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0300","first-page":"68","article-title":"Unusual and memorable. Chrysiasis secondary to sodium aurothiomalate treatment","volume":"58","author":"Langan","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/rheumatology\/36.1.3","article-title":"Chrysiasis","volume":"36","author":"Smith","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0310","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0190-9622(07)80006-5","article-title":"Chrysiasis after low-dose gold and UV light exposure","volume":"34","author":"Fleming","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0315","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/BF02031980","article-title":"Chrysiasis in rheumatoid arthritis","volume":"9","author":"Bonet","year":"1990","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0320","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1600-0560.1984.tb00408.x","article-title":"Chrysiasis following gold therapy for rheumatoid arthritis: ultrastructural analysis with x-ray energy spectroscopy","volume":"11","author":"Pelachyk","year":"1984","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0325","first-page":"773","article-title":"Chrysiasis resulting from gold therapy in rheumatoid arthritis: identification of gold by x-ray microanalysis","volume":"57","author":"Beckett","year":"1982","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2014.01.052_bb0330","first-page":"28","article-title":"Quantitation of gold in skin in chrysiasis","volume":"2","author":"Jeffery","year":"1975","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0335","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.autrev.2012.12.001","article-title":"The use of glucocorticoids in systemic lupus erythematosus. After 60years still more an art than science","volume":"12","author":"Luijten","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0340","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0345","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0306-3623(96)00419-3","article-title":"The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines","volume":"29","author":"Bondeson","year":"1997","journal-title":"Gen Pharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0350","doi-asserted-by":"crossref","first-page":"715","DOI":"10.5694\/j.1326-5377.1965.tb72107.x","article-title":"A case of dermatomyositis treated with 6-mercaptopurine and azathioprine","volume":"1","author":"Goldstein","year":"1965","journal-title":"Med J Aust"},{"key":"10.1016\/j.autrev.2014.01.052_bb0355","first-page":"275","article-title":"Clinical trial of azathioprine, a new antileukaemic compound","volume":"7","author":"Eridani","year":"1965","journal-title":"Panminerva Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0360","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0365","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0140-6736(04)16808-6","article-title":"Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial","volume":"364","author":"Remuzzi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.01.052_bb0370","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1191\/096120301676669495","article-title":"Azathioprine therapy for patients with systemic lupus erythematosus","volume":"10","author":"Abu-Shakra","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.052_bb0375","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00128071-200708020-00004","article-title":"Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris","volume":"8","author":"Olszewska","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0380","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.01.052_bb0385","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2174\/13894501113149990172","article-title":"Is there still a room for azathioprine monotherapy in inflammatory bowel disease?","volume":"14","author":"Bourrier","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.autrev.2014.01.052_bb0390","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MIB.0b013e318281d697","article-title":"Early azathioprine in Crohn's disease","volume":"19","author":"Cosnes","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0395","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cgh.2012.10.038","article-title":"Long-term outcome of patients with Crohn's disease who respond to azathioprine","volume":"11","author":"Camus","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0400","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2014.01.052_bb0405","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/gut.2004.053231","article-title":"Risks and benefits of azathioprine therapy","volume":"54","author":"McGovern","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2014.01.052_bb0410","first-page":"CD001461","article-title":"Azathioprine for treating rheumatoid arthritis","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.01.052_bb0415","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1177\/096120339600500103","article-title":"Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.052_bb0420","first-page":"23","article-title":"Chloroquine and hydroxychloroquine inhibit multiple sites in metabolic pathways leading to neutrophil superoxide release","volume":"15","author":"Hurst","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0425","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/01.wnl.0000265055.28218.cc","article-title":"Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy","volume":"69","author":"Niermeijer","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2014.01.052_bb0430","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.22662","article-title":"Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia","volume":"109","author":"Shanafelt","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2014.01.052_bb0435","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02841860600871087","article-title":"Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer","volume":"46","author":"Lindman","year":"2007","journal-title":"Acta Oncol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0440","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1200\/JCO.2006.07.0847","article-title":"Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stages I and II breast cancer: final analysis from INT-0137 (S9313)","volume":"25","author":"Linden","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0445","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.leukres.2006.09.021","article-title":"High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma","volume":"31","author":"Benson","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.autrev.2014.01.052_bb0450","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","article-title":"Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia","volume":"109","author":"Kay","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.01.052_bb0455","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2012.08.018","article-title":"Lupus nephritis: a critical review","volume":"12","author":"Borchers","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0460","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts","volume":"11","author":"Diaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0465","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/mpo.2950160603","article-title":"Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis","volume":"16","author":"Luce","year":"1988","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0470","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1200\/JCO.1991.9.11.2016","article-title":"Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation","volume":"9","author":"Shepherd","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0475","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.autrev.2014.01.052_bb0480","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0022-3476(82)80564-7","article-title":"Liver and kidney transplantation in children receiving cyclosporin A and steroids","volume":"100","author":"Starzl","year":"1982","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2014.01.052_bb0485","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJM198107303050507","article-title":"Liver transplantation with use of cyclosporin a and prednisone","volume":"305","author":"Starzl","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0490","first-page":"281","article-title":"Liver transplantation, 1980, with particular reference to cyclosporin-A","volume":"13","author":"Starzl","year":"1981","journal-title":"Transplant Proc"},{"key":"10.1016\/j.autrev.2014.01.052_bb0495","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/brb3.16","article-title":"Neuroprotective effects of tacrolimus (FK-506) and cyclosporin (CsA) in oxidative injury","volume":"1","author":"Yousuf","year":"2011","journal-title":"Brain Behav"},{"key":"10.1016\/j.autrev.2014.01.052_bb0500","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0002-9343(56)90066-3","article-title":"Penicillamine, a new oral therapy for Wilson's disease","volume":"21","author":"Walshe","year":"1956","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0505","first-page":"67","article-title":"Penicillamine in the treatment of rheumatoid arthritis","volume":"70","author":"Camp","year":"1977","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0510","doi-asserted-by":"crossref","first-page":"652","DOI":"10.7326\/0003-4819-97-5-652","article-title":"D-penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis","volume":"97","author":"Steen","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0515","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/15476910490496258","article-title":"Investigation of the involvement of macrophages and T cells in D-penicillamine-induced autoimmunity in the Brown Norway rat","volume":"1","author":"Masson","year":"2004","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0520","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1021\/tx0498399","article-title":"D-penicillamine-induced autoimmunity in the Brown Norway rat: role for both T and non-T splenocytes in adoptive transfer of tolerance","volume":"17","author":"Seguin","year":"2004","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0525","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/tx034195a","article-title":"Tolerance induced by low dose D-penicillamine in the brown Norway rat model of drug-induced autoimmunity is immune-mediated","volume":"17","author":"Masson","year":"2004","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0530","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1021\/tx900128p","article-title":"D-penicillamine-induced autoimmunity: relationship to macrophage activation","volume":"22","author":"Li","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0535","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1021\/tx900087z","article-title":"Covalent binding of penicillamine to macrophages: implications for penicillamine-induced autoimmunity","volume":"22","author":"Li","year":"2009","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0540","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.48.7.609","article-title":"Fatal aplastic anaemia and liver toxicity caused by D-penicillamine treatment of rheumatoid arthritis","volume":"48","author":"Fishel","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0545","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-3565(25)24292-6","article-title":"The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism","volume":"272","author":"Cherwinski","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2014.01.052_bb0550","article-title":"A longterm prospective real-life experience with leflunomide in juvenile idiopathic arthritis","author":"Alcantara","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0555","first-page":"542","article-title":"Renal infarct in rheumatic heart disease. Anatomoclinical study of 210 cases","volume":"38","author":"De Leon","year":"1968","journal-title":"Arch Inst Cardiol Mex"},{"key":"10.1016\/j.autrev.2014.01.052_bb0560","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1749-6632.1994.tb24773.x","article-title":"Minocycline in active rheumatoid arthritis. A placebo-controlled trial","volume":"732","author":"Kloppenburg","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2014.01.052_bb0565","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/art.1780370505","article-title":"Minocycline in active rheumatoid arthritis. A double-blind, placebo-controlled trial","volume":"37","author":"Kloppenburg","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0570","first-page":"43","article-title":"Minocycline treatment for rheumatoid arthritis: an open dose finding study","volume":"17","author":"Breedveld","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0575","first-page":"143","article-title":"Acute hepatitis and drug-related lupus induced by minocycline treatment","volume":"92","author":"Golstein","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0580","first-page":"1641","article-title":"Minocycline-induced liver injury","volume":"91","author":"Malcolm","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0585","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2133.1993.tb03519.x","article-title":"Skin pigmentation due to minocycline treatment of facial dermatoses","volume":"129","author":"Dwyer","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0590","doi-asserted-by":"crossref","first-page":"476","DOI":"10.7326\/0003-4819-117-6-476","article-title":"Minocycline-induced cell-mediated hypersensitivity pneumonitis","volume":"117","author":"Guillon","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0595","first-page":"476","article-title":"Salicylazosulfapyridine (salazopyrin or azopyrin) in rheumatoid arthritis and experimental polyarthritis","volume":"73","author":"Kuzell","year":"1950","journal-title":"Calif Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0600","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(62)92080-9","article-title":"Sulphasalazine and salicylazosulphadimidine in ulcerative colitis","volume":"1","author":"Baron","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.01.052_bb0605","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archderm.142.10.1337","article-title":"Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine","volume":"142","author":"McGirt","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0610","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.1964.03070140077021","article-title":"Hemolytic anemia secondary to salicylazosulfapyridine therapy","volume":"190","author":"Gardner","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2014.01.052_bb0615","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1136\/pgmj.2006.055194","article-title":"Sulfasalazine-induced immune thrombocytopenia","volume":"83","author":"Cantarini","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.autrev.2014.01.052_bb0620","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1139\/m73-237","article-title":"Relationship between the biosynthesis of virus-like particles and mycophenolic acid in Penicillium stoloniferum and Penicillium brevicompactum","volume":"19","author":"Detroy","year":"1973","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0625","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00007691-199512000-00023","article-title":"Mechanism of action of mycophenolate mofetil","volume":"17","author":"Ransom","year":"1995","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.autrev.2014.01.052_bb0630","doi-asserted-by":"crossref","first-page":"R182","DOI":"10.1186\/ar2093","article-title":"Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis","volume":"8","author":"Moore","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2014.01.052_bb0635","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"D'Cruz","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.01.052_bb0640","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2012.11.002","article-title":"Autoimmune hepatitis: a comprehensive review","volume":"41","author":"Liberal","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0645","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/193140a0","article-title":"Increased level of dihydrofolic reductase in leucocytes of patients treated with amethopterin","volume":"193","author":"Bertino","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2014.01.052_bb0650","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000203749","article-title":"Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid)","volume":"4","author":"Meyer","year":"1950","journal-title":"Acta Haematol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0655","first-page":"269","article-title":"The effect of triethylene melamine, aureomycin, and some 4-amino derivatives of folic acid on tissues in vitro","volume":"12","author":"Antikajian","year":"1951","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.autrev.2014.01.052_bb0660","first-page":"211","article-title":"An evaluation of folic acid antagonists in adults with neoplastic diseases: a study of 93 patients with incurable neoplasms","volume":"43","author":"Wright","year":"1951","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.autrev.2014.01.052_bb0665","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3181\/00379727-93-22757","article-title":"Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma","volume":"93","author":"Hertz","year":"1956","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0670","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00162840","article-title":"Between fact and technique: the beginnings of hybridoma technology","volume":"25","author":"Cambrosio","year":"1992","journal-title":"J Hist Biol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0675","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2014.01.052_bb0680","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/08830189509061738","article-title":"Human antibodies from transgenic mice","volume":"13","author":"Lonberg","year":"1995","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0685","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/bfgp\/1.2.189","article-title":"Concepts in antibody phage display","volume":"1","author":"Carmen","year":"2002","journal-title":"Brief Funct Genomic Proteomic"},{"key":"10.1016\/j.autrev.2014.01.052_bb0690","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1073\/pnas.61.4.1250","article-title":"Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin","volume":"61","author":"Kolb","year":"1968","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2014.01.052_bb0695","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1084\/jem.128.6.1267","article-title":"Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. 3. Analysis of mechanism","volume":"128","author":"Ruddle","year":"1968","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0700","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1084\/jem.128.6.1255","article-title":"Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. II. Correlation of the in vitro response with skin reactivity","volume":"128","author":"Ruddle","year":"1968","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0705","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1084\/jem.128.6.1237","article-title":"Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon","volume":"128","author":"Ruddle","year":"1968","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0710","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2014.01.052_bb0715","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","article-title":"The TNF and TNF receptor superfamilies: integrating mammalian biology","volume":"104","author":"Locksley","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2014.01.052_bb0720","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","article-title":"Tumor necrosis factor signaling","volume":"10","author":"Wajant","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.autrev.2014.01.052_bb0725","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1071924","article-title":"TNF-R1 signaling: a beautiful pathway","volume":"296","author":"Chen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.autrev.2014.01.052_bb0730","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1101\/gad.17224711","article-title":"TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway","volume":"25","author":"Kant","year":"2011","journal-title":"Genes Dev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0735","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0006-2952(03)00490-8","article-title":"Regulation of proliferation, survival and apoptosis by members of the TNF superfamily","volume":"66","author":"Gaur","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0740","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0745","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.174.6.1483","article-title":"A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity","volume":"174","author":"Peppel","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0750","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.151.10.5699","article-title":"Expression of a TNF inhibitor in transgenic mice","volume":"151","author":"Peppel","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0755","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1073\/pnas.91.1.215","article-title":"Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer","volume":"91","author":"Kolls","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2014.01.052_bb0760","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0765","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0770","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0775","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0780","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.autrev.2012.03.010","article-title":"Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship?","volume":"12","author":"Efe","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0785","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","article-title":"A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores","volume":"43","author":"Jiang","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0790","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1586\/1744666X.2.3.331","article-title":"Anakinra in the treatment of rheumatic disease","volume":"2","author":"Fleischmann","year":"2006","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2014.01.052_bb0795","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/ard.2005.048371","article-title":"Safety of extended treatment with anakinra in patients with rheumatoid arthritis","volume":"65","author":"Fleischmann","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0800","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1136\/ard.2011.152728","article-title":"Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes","volume":"70","author":"Kuemmerle-Deschner","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0805","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2012.07.027","article-title":"Biologic drugs in autoinflammatory syndromes","volume":"12","author":"Caorsi","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0810","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.autrev.2012.07.018","article-title":"Autoinflammation and autoimmunity: bridging the divide","volume":"12","author":"Doria","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0815","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2012.12.010","article-title":"The pathogenesis of neonatal autoimmune and autoinflammatory diseases: a comprehensive review","volume":"41","author":"Chang","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0820","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0825","article-title":"The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","author":"Cambridge","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb0830","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0835","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.rdc.2004.01.006","article-title":"B lymphocyte depletion therapy with rituximab in rheumatoid arthritis","volume":"30","author":"Edwards","year":"2004","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2014.01.052_bb0840","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/ard.2007.085787","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0845","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.autrev.2011.10.012","article-title":"To switch or not to switch after a poor response to a TNFalpha blocker? It is not only a matter of ACR20 OR ACR50","volume":"11","author":"Buch","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0850","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/art.23732","article-title":"Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I\/II randomized, blinded, placebo-controlled, dose-ranging study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0855","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.autrev.2013.06.011","article-title":"Long-term safety of abatacept in patients with rheumatoid arthritis","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0860","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2013.06.008","article-title":"Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?","volume":"13","author":"Caporali","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0865","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.autrev.2013.01.001","article-title":"Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis","volume":"12","author":"Cutolo","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0870","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.01.052_bb0875","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","article-title":"Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"378","author":"Orban","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.01.052_bb0880","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/art.34624","article-title":"Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions","volume":"64","author":"Wofsy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0885","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.01.052_bb0890","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.01.052_bb0895","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00063030-200923010-00006","article-title":"Ustekinumab","volume":"23","author":"Weber","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2014.01.052_bb0900","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study","author":"Mariette","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb0905","first-page":"149","article-title":"Belimumab. No tangible efficacy but a risk of immunosuppression","volume":"22","year":"2013","journal-title":"Prescrire Int"},{"key":"10.1016\/j.autrev.2014.01.052_bb0910","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.37995","article-title":"Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb0915","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1056\/NEJMct1207259","article-title":"Belimumab for systemic lupus erythematosus","volume":"368","author":"Hahn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0920","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/0961203313476154","article-title":"Belimumab for systemic lupus erythematosus: a practice-based view","volume":"22","author":"Parodis","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.052_bb0925","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0961203312471575","article-title":"Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy","volume":"22","author":"Mosak","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.052_bb0930","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.052_bb0935","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/0961203312469259","article-title":"Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus","volume":"22","author":"Wallace","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2014.01.052_bb0940","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb0945","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1177\/1060028013512790","article-title":"Tofacitinib: the first Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis","volume":"47","author":"Vyas","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.autrev.2014.01.052_bb0950","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2474-14-332","article-title":"Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies","volume":"14","author":"Berhan","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2014.01.052_bb0955","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.113.209304","article-title":"Preclinical to clinical translation of tofacitinib, a janus kinase inhibitor, in rheumatoid arthritis","volume":"348","author":"Dowty","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.autrev.2014.01.052_bb0960","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14656566.2014.854771","article-title":"Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib","volume":"15","author":"Yamaoka","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.autrev.2014.01.052_bb0965","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2474-14-298","article-title":"Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"14","author":"He","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2014.01.052_bb0970","first-page":"1-26","article-title":"Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis","volume":"159","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0975","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb0980","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3346\/jkms.2013.28.8.1134","article-title":"Tofacitinib prevents radiographic progression in rheumatoid arthritis","volume":"28","author":"Kim","year":"2013","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.autrev.2014.01.052_bb0985","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s12325-013-0047-y","article-title":"Tofacitinib for treatment of rheumatoid arthritis","volume":"30","author":"Rakieh","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.autrev.2014.01.052_bb0990","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-013-0065-8","article-title":"Tofacitinib: a review of its use in adult patients with rheumatoid arthritis","volume":"73","author":"Scott","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2014.01.052_bb0995","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0140-6736(13)61114-9","article-title":"Tofacitinib for rheumatoid arthritis","volume":"381","author":"Gremese","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2014.01.052_bb1000","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1517\/17425255.2013.789500","article-title":"A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis","volume":"9","author":"Bannwarth","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X12470753","article-title":"The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential","volume":"5","author":"Cutolo","year":"2013","journal-title":"Ther Adv Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2014.01.052_bb1010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb1015","first-page":"1","article-title":"Tofacitinib (Xeljanz) for rheumatoid arthritis","volume":"55","year":"2013","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.autrev.2014.01.052_bb1020","first-page":"2120","article-title":"FDA approves tofacitinib for rheumatoid arthritis","volume":"69","author":"Traynor","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.autrev.2014.01.052_bb1025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/s10165-012-0799-2","article-title":"JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical","volume":"23","author":"Tanaka","year":"2013","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1358\/dot.2012.48.8.1855926","article-title":"Tofacitinib for the treatment of moderate to severe rheumatoid arthritis","volume":"48","author":"de Lartigue","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.autrev.2014.01.052_bb1035","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb1040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb1045","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/eci.12.19","article-title":"Tofacitinib for the treatment of rheumatoid arthritis","volume":"8","author":"Zerbini","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1050","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/acr.20494","article-title":"Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"63","author":"Tanaka","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2014.01.052_bb1055","article-title":"The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib","author":"Bushmakin","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.autrev.2014.01.052_bb1060","first-page":"304","article-title":"Tofacitinib and other kinase inhibitors in the treatment of psoriasis","volume":"104","author":"Ortiz-Ibanez","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.autrev.2014.01.052_bb1065","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1070","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMc1211073","article-title":"Tofacitinib in active ulcerative colitis","volume":"367","author":"Paul","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb1075","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1053\/j.gastro.2013.03.036","article-title":"Tofacitinib: janus bifrons in ulcerative colitis treatment","volume":"144","author":"Peyrin-Biroulet","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2014.01.052_bb1080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb1085","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4166\/kjg.2013.61.6.354","article-title":"The efficacy and safety of a tofacitinib in the treatment of active ulcerative colitis","volume":"61","author":"Seo","year":"2013","journal-title":"Korean J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1090","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/13894501113149990160","article-title":"Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment","volume":"14","author":"Vuitton","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.autrev.2014.01.052_bb1095","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/TP.0b013e3182626b5a","article-title":"Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients","volume":"94","author":"Vafadari","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.autrev.2014.01.052_bb1100","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1111\/j.1600-6143.2012.04127.x","article-title":"Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.autrev.2014.01.052_bb1105","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1517\/13543784.2013.811231","article-title":"Tofacitinib in kidney transplantation","volume":"22","author":"Wojciechowski","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2014.01.052_bb1110","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/infdis\/jis269","article-title":"Risk of tuberculosis reactivation with tofacitinib (CP-690550)","volume":"205","author":"Maiga","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb1115","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1125","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.25511","article-title":"Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis","volume":"55","author":"Jin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2014.01.052_bb1130","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.24757","article-title":"Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis","volume":"55","author":"Takahashi","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2014.01.052_bb1135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2014.01.052_bb1140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.24630","article-title":"Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis","volume":"55","author":"Lleo","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2014.01.052_bb1145","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/hep.26067","article-title":"Therapeutic effect of cytotoxic T lymphocyte antigen 4\/immunoglobulin on a murine model of primary biliary cirrhosis","volume":"57","author":"Dhirapong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2014.01.052_bb1150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2013.01.008","article-title":"Genetic susceptibility to SLE: recent progress from GWAS","volume":"41","author":"Cui","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2013.01.010","article-title":"The critical importance of epigenetics in autoimmunity","volume":"41","author":"Lu","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaut.2013.01.012","article-title":"Systemic sclerosis: genetics and epigenetics","volume":"41","author":"Luo","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2013.05.003","article-title":"Rethinking mechanisms of autoimmune pathogenesis","volume":"45","author":"Pillai","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jaut.2013.02.003","article-title":"Genetic association, seasonal infections and autoimmune basis of narcolepsy","volume":"43","author":"Singh","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1175","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.autrev.2010.06.012","article-title":"The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis","volume":"11","author":"Fabris","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1180","article-title":"DNA methylation profiles in type 1 diabetes twins point to strong epigenetic effects on etiology","author":"Stefan","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaut.2013.04.003","article-title":"Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients","volume":"43","author":"Coit","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1190","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaut.2012.12.004","article-title":"FOXP3: genetic and epigenetic implications for autoimmunity","volume":"41","author":"Katoh","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaut.2013.01.001","article-title":"Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris","volume":"41","author":"Zhang","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jaut.2013.02.002","article-title":"Epigenetic dysregulation in salivary glands from patients with primary Sjogren's syndrome may be ascribed to infiltrating B cells","volume":"41","author":"Thabet","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1205","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2013.01.009","article-title":"DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes","volume":"41","author":"Wang","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1210","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaut.2013.01.005","article-title":"Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus","volume":"41","author":"Zhang","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1215","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaut.2012.12.001","article-title":"The impact of genes on the occurrence of autoantibodies in rheumatoid arthritis. A study on disease discordant twin pairs","volume":"41","author":"Svendsen","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaut.2013.07.005","article-title":"Geoepidemiology of primary sclerosing cholangitis: a critical review","volume":"46","author":"Tanaka","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1225","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2013.07.003","article-title":"The role of miRNA in inflammation and autoimmunity","volume":"12","author":"Singh","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.07.002","article-title":"MicroRNAs in autoimmunity and inflammatory bowel disease: crucial regulators in immune response","volume":"11","author":"Iborra","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1235","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2011.05.009","article-title":"MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"11","author":"Thamilarasan","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaut.2012.12.013","article-title":"Overexpression of microRNA-21 is associated with elevated pro-inflammatory cytokines in dominant-negative TGF-beta receptor type II mouse","volume":"41","author":"Ando","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1245","doi-asserted-by":"crossref","first-page":"7947","DOI":"10.3748\/wjg.v19.i44.7947","article-title":"MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases","volume":"19","author":"De Iudicibus","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1250","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.autrev.2012.10.004","article-title":"Stem cells in autoimmune diseases: implications for pathogenesis and future trends in therapy","volume":"12","author":"Cipriani","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2014.01.052_bb1255","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1260","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaut.2013.06.007","article-title":"Interleukin-7: fuel for the autoimmune attack","volume":"45","author":"Dooms","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1265","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.autrev.2013.03.015","article-title":"Biologic therapies and systemic bone loss in rheumatoid arthritis","volume":"12","author":"Dimitroulas","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1270","article-title":"Anti-CD4 treatment inhibits autoimmunity in scurfy mice through the attenuation of co-stimulatory signals","author":"Mayer","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1275","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.autrev.2013.02.005","article-title":"Is it time for biosimilars in autoimmune diseases?","volume":"12","author":"Cuadrado","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Ben-Horin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1285","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.autrev.2012.11.011","article-title":"The impact of the profile of biologics on treatment costs","volume":"12","author":"Leardini","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1290","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.autrev.2012.11.010","article-title":"Tight control applied to the biological therapy of rheumatoid arthritis","volume":"12","author":"Epis","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1295","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.autrev.2011.10.020","article-title":"Systemic lupus erythematosus one disease or many?","volume":"11","author":"Agmon-Levin","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1300","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jaut.2012.05.008","article-title":"Sjogren's syndrome at the crossroad of polyautoimmunity","volume":"39","author":"Amador-Patarroyo","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2014.01.052_bb1305","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2012.02.002","article-title":"Common mechanisms of autoimmune diseases (the autoimmune tautology)","volume":"11","author":"Anaya","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1310","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.autrev.2011.10.004","article-title":"Are autoimmune diseases predictable?","volume":"11","author":"Tobon","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1315","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.autrev.2012.10.020","article-title":"Different effects of biological drugs in rheumatoid arthritis","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.01.052_bb1320","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molimm.2012.04.007","article-title":"Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus","volume":"52","author":"Yuan","year":"2012","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1325","doi-asserted-by":"crossref","first-page":"6773","DOI":"10.4049\/jimmunol.0904060","article-title":"MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1","volume":"184","author":"Pan","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1330","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/emmm.201100171","article-title":"Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice","volume":"3","author":"Garchow","year":"2011","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb1335","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nm.2815","article-title":"The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha","volume":"18","author":"Zhu","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2014.01.052_bb1340","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1002\/art.34596","article-title":"Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus","volume":"64","author":"Fan","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb1345","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/art.34334","article-title":"Down-regulation of microRNA-34a* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance","volume":"64","author":"Niederer","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb1350","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/0961203312465779","article-title":"MicroRNA-101, mitogen-activated protein kinases and mitogen-activated protein kinases phosphatase-1 in systemic lupus erythematosus","volume":"22","author":"Yang","year":"2013","journal-title":"Lupus"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.01.052_bb1355","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2010.138669","article-title":"miR-124a as a key regulator of proliferation and MCP-1 secretion in synoviocytes from patients with rheumatoid arthritis","volume":"70","author":"Kawano","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2014.01.052_bb1360","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.27632","article-title":"MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus","volume":"62","author":"Zhao","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb1365","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1073\/pnas.1200081109","article-title":"MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappa B pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20)","volume":"109","author":"Kim","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2014.01.052_bb1370","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/art.30196","article-title":"MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1","volume":"63","author":"Zhao","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb1375","doi-asserted-by":"crossref","first-page":"e1002128","DOI":"10.1371\/journal.pgen.1002128","article-title":"A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus","volume":"7","author":"Luo","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.autrev.2014.01.052_bb1380","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/ar2493","article-title":"Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients","volume":"10","author":"Pauley","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2014.01.052_bb1385","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2474-11-209","article-title":"MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients","volume":"11","author":"Niimoto","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2014.01.052_bb1390","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1440-1797.2012.01573.x","article-title":"Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis","volume":"17","author":"Lu","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.autrev.2014.01.052_bb1395","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10067-011-1857-4","article-title":"Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1400","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s10753-012-9467-0","article-title":"Association of microRNA-146a with autoimmune diseases","volume":"35","author":"Xu","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.autrev.2014.01.052_bb1405","doi-asserted-by":"crossref","first-page":"11193","DOI":"10.1073\/pnas.1019536108","article-title":"MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis","volume":"108","author":"Kurowska-Stolarska","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2014.01.052_bb1410","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/art.30115","article-title":"Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation","volume":"63","author":"Stanczyk","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2014.01.052_bb1415","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2249.2012.04676.x","article-title":"Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis","volume":"171","author":"Lu","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2014.01.052_bb1420","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1136\/annrheumdis-2011-200803","article-title":"Identification of microRNA-221\/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model","volume":"71","author":"Pandis","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:31:54Z","timestamp":1746117114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214000640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":284,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1568997214000640"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.01.052","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet needs in the treatment of autoimmunity: From aspirin to stem cells","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.01.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}